Vir Biotechnology, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2021
August 05, 2021 at 04:05 pm EDT
Share
Vir Biotechnology, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2021. For the quarter, the company reported total revenue of $177.068 million against $66.988 million a year ago. Income from operations was $61.017 million against loss from operations of $29.051 million a year ago. Net income was $61.813 million against net loss of $31.167 million a year ago. Net income per basic share was $0.48 against net loss per basic share of $0.27 a year ago. Net income per diluted share was $0.46 against net loss per diluted share of $0.27 a year ago.
For the six months, the company reported total revenue of $179.052 million against $72.706 million a year ago. Loss from operations was $97.616 million against $100.961 million a year ago. Net loss was $107.098 million against $108.407 million a year ago. Net loss per basic share was $0.83 against $0.97 a year ago.
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.
VIR BIOTECHNOLOGY, INC. 
